The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival
Abstract
Introduction Abbreviations used in this article: ACA, anticentromere autoantibodies, anti-topo I, autoantibodies to DNA-topoisomerase I, CSR, cumulative survival rates, DLCO, carbon monoxide diffusion capacity of the lungs, ECG, electrocardiogram, ESR, erythrocyte sedimentation rate, MCP, metacarpophalangeal joints, NCM, nailfold capillary microscopy, RA, rheumatoid arthritis, SLE, systemic lupus erythematosus, SMR, standardized mortality ratios, SSc, systemic sclerosis Systemic sclerosis (SSc), or scleroderma, is a systemic autoimmune disease characterized by microvascular involvement, fibroblast activation and excessive production of collagen with resulting skin and visceral fibrosis, and the presence of specific autoantibodies. The skin, lungs, gastrointestinal system, heart, and kidneys are major SSc targets. Raynaud phenomenon is present in most patients. The microvascular damage is reflected in nailfold capillary changes readily identified by nailfold capillary microscopy (NCM), including capillary loss and dilatations (19,29). Autoantibodies to centromeres (ACA) and to DNA-topoisomerase I (anti-topo I) are also strongly associated with SSc (47,51). SSc has a worldwide distribution (42). For example, SSc populations have been characterized in patients from the United States (3,43), France (14,33,48), Japan (22,39), Australia (4), and in English Canadians (25). Genetic background modulates the expression of SSc, particularly autoantibodies (21,38). French Canadians are the descendants of approximately 10,000 emigrants from France who settled in Canada between 1608 and 1760 (24). Due to a combination of historic factors, including the 1760 Conquest of New France by England, and the implementation of English rule in 1763, which led to cessation of immigration from France, French Canadians developed relatively in isolation well into the 20th century. Co-assimilation between English and French Canadians did not occur. The resulting relative genetic homogeneity confined in the same geographic environment makes it of interest to study expression of genetically modulated diseases (5,15). Therefore we and others have been studying systemic autoimmune diseases in this population (13,35,41,49). Since, to our knowledge, no detailed study has reported thus far on SSc in French Canadians, the first objective of this report was to describe SSc features at diagnosis in this population. Mortality and factors predictive for decreased survival in patients with SSc have been the focus of interest for over 30 years (32). However, review of the literature revealed limitations in data interpretation due to small sample size, exclusion of certain patients with SSc, lack of uniform definitions for subsets, less than optimal date of entry into study, lack of use of multivariate analysis to identify factors predictive for mortality, and omission of standardized mortality ratios (SMR) to assess the mortality burden due to SSc in comparison with the general population. Relatively few studies have avoided these pitfalls (2,7,18,25). Therefore, the second objective of this report was to use multivariate analysis to identify at diagnosis factors predictive for mortality in our large cohort of well-defined patients encompassing the full spectrum of SSc. We were particularly interested in defining the predictive value of ACA, anti-topo I, and NCM. We also wished to determine SMR in our patient population, and to compare our data with other major series. Patients and Methods Design and patients A prospective cohort design was used. Between 7 April 1984 and 22 September 1999, SSc was diagnosed at first presentation in 309 new, consecutive, and unselected French Canadian patients at the Connective Tissue Diseases and Vascular Medicine Clinics of Notre-Dame Hospital in Montreal, a tertiary care academic center and a major French Canadian hospital founded in 1880. The clinical diagnosis of SSc was made without awareness of NCM, ACA, and anti-topo I results. Patients were classified as French Canadians if their 4 grandparents were French Canadians. SSc subsets Patients were classified as fulfilling American College of Rheumatology (ACR) 1980 preliminary SSc criteria or not, based on the presence or absence of the major criterion, that is, sclerodermatous skin involvement proximal to metacarpophalangeal (MCP) joints (including facial skin thickening), or 2 or more of the minor criteria: 1) sclerodactyly, 2) digital pitting scars or loss of substance of the distal finger pad, and 3) bibasilar pulmonary fibrosis (46). Because ACR SSc criteria exclude some patients who have received a diagnosis of definitive SSc from experienced clinicians (12,36,40,53), patients were also categorized into 1 of 4 SSc subsets using a slightly modified version of the definitions described by Barnett et al (4), Giordano et al (12), and Ferri et al (11) and based on the extent of sclerodermatous skin involvement, as shown in Figure 1: diffuse (must include trunk in
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Feinstein, A. R., Sosin, D. M., & Wells, C. K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198506203122504 · Cited by 1,544
Criteria for the classification of early systemic sclerosis.
LeRoy, E. C., & Medsger, T. A. (2001) · PubMed · Cited by 1,384
Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy
Brais, B., Bouchard, J.-P., Xie, Y.-G., Rochefort, D. L., Chrétien, N., Tomé, F. M. S., Lafrentére, R. G., Rommens, J. M., Uyama, E., Nohira, O., et al. (1998) · Nature Genetics · doi:10.1038/ng0298-164 · Cited by 805
Steen, V. D., Powell, D. L., & Medsger, T. A. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310207 · Cited by 573
Diversity of antinuclear antibodies in progressive systemic sclerosis
Tan, E. M., Rodnan, G. P., Garcia, I., Moroi, Y., Fritzler, M. J., & Peebles, C. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230602 · Cited by 524
D-Penicillamine Therapy in Progressive Systemic Sclerosis (Scleroderma): A Retrospective Analysis
STEEN, V. D., MEDSGER, T. A., & RODNAN, G. P. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-5-652 · Cited by 322
MEDSGER, T. A., MASI, A. T., RODNAN, G. P., BENEDEK, T. G., & ROBINSON, H. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-75-3-369 · Cited by 321
Predictors of survival in systemic sclerosis (Scleroderma)
Altman, R. D., Medsger, T. A., Bloch, D. A., & Michel, B. A. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340405 · Cited by 298
Cited by
Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230
Mayes, M. D., Lacey, J. V., Beebe‐Dimmer, J., Gillespie, B. W., Cooper, B., Laing, T. J., & Schottenfeld, D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11073 · Cited by 935
Interstitial lung disease guideline
Wells, A. U., Hirani, N., & on behalf of the BTS Interstitial Lung Disease Guideline Group, A. S. O. T. B. T. S. S. O. C. C. (2008) · Thorax · doi:10.1136/thx.2008.101691 · Cited by 866
Mapping and predicting mortality from systemic sclerosis
Elhai, M., Meune, C., Boubaya, M., Avouac, J., Hachulla, E., Balbir-Gurman, A., Riemekasten, G., Airò, P., Joven, B., Vettori, S., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211448 · Cited by 691
Koenig, M., Joyal, F., Fritzler, M. J., Roussin, A., Abrahamowicz, M., Boire, G., Goulet, J., Rich, É., Grodzicky, T., Raymond, Y., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24038 · Cited by 615
Self-citation
Metadata
- Authors
- SCUSSEL-LONZETTI, L., JOYAL, F., RAYNAULD, J.-P., ROUSSIN, A., RICH, É., GOULET, J.-R., RAYMOND, Y., & SENÉCAL, J.-L.
- Venue
- Medicine
- Published
- 2002-03
- Volume
- 81
- Issue
- 2
- Pages
- 154-167
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2051302134
- Cited by
- 361
- References
- 23
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival. https://app.cochat.ai/papers/10.1097/00005792-200203000-00005
- The paper
- SCUSSEL-LONZETTI, L., JOYAL, F., RAYNAULD, J.-P., ROUSSIN, A., RICH, É., GOULET, J.-R., RAYMOND, Y., & SENÉCAL, J.-L. (2002). Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival. Medicine. https://doi.org/10.1097/00005792-200203000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.